ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.130
-0.010 (-7.14%)
At close: Dec 5, 2025, 4:00 PM EST
0.133
+0.003 (2.08%)
After-hours: Dec 5, 2025, 7:58 PM EST

Company Description

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.

It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster.

It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer’s disease.

In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19.

It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores.

The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs, Inc.
ProPhase Labs logo
Country United States
Founded 1989
IPO Date Jan 16, 1997
Industry Diagnostics & Research
Sector Healthcare
Employees 96
CEO Ted Karkus

Contact Details

Address:
711 Stewart Avenue, Suite 200
Garden City, New York 11530
United States
Phone 215 345 0919
Website prophaselabs.com

Stock Details

Ticker Symbol PRPH
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000868278
CUSIP Number 74345W108
ISIN Number US74345W1080
Employer ID 23-2577138
SIC Code 2834

Key Executives

Name Position
Ted William Karkus Chairman and Chief Executive Officer
Steven M. Plumb CPA Chief Financial Officer
Kamal Obbad Senior Vice President and Director of Sales and Marketing - Nebula Genomics
Jason Karkus President of Nebula Genomics
Lance Bisesar Corporate Controller

Latest SEC Filings

Date Type Title
Nov 26, 2025 8-K Current Report
Nov 25, 2025 8-K Current Report
Nov 25, 2025 8-K Current Report
Nov 19, 2025 10-Q Quarterly Report
Nov 19, 2025 8-K Current Report
Nov 14, 2025 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Oct 31, 2025 DEF 14A Other definitive proxy statements
Oct 21, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Oct 21, 2025 PRE 14A Other preliminary proxy statements
Oct 15, 2025 424B5 Filing